ABSTRACT
INTRODUCTION
Women in the UK are offered a mid-trimester fetal anomaly ultrasound scan at approximately 20 weeks of gestation, with the aim of identifying serious abnormalities incompatible with life or associated with morbidity, as set out by the national fetal anomaly screening program. Some abnormalities, however, are recognized for the first time only later in pregnancy, when further ultrasound screening might be performed for indications such as monitoring fetal growth or investigating reduced fetal movements. Fetal brain abnormalities are amongst the commonest lesions recognized on antenatal ultrasound and are associated with high risk of detrimental long-term neurodevelopmental outcome. Enlargement of the lateral cerebral ventricles, or ventriculomegaly (VM), is by far the commonest intracranial abnormality identified on prenatal ultrasound (approximately 2.5/1000 pregnancies 1 ), but the clinical significance of this finding is complex.
VM can be associated with other structural abnormalities (in which case the prognosis is usually poor), but most often it is the only abnormal intracranial finding. In this situation, prognosis is related to the degree of VM, with fetuses with larger ventricles generally having a higher risk of poor neurodevelopmental outcome.
The 'Magnetic resonance imaging to enhance the diagnosis of fetal developmental brain abnormalities in utero' (MERIDIAN) study 2 was a multicenter prospective cohort study based in the UK, designed to evaluate the diagnostic and clinical benefit of fetal magnetic resonance imaging (MRI) in the antenatal diagnosis of fetal brain pathology. The overall findings of the MERIDIAN cohort have been reported previously 3 and support a major diagnostic and management impact when fetal MRI is included in the diagnostic pathway. At the planning stage of the study, focus groups of fetal medicine consultants were asked about the information the MERIDIAN study should attempt to provide in order to improve clinical practice; the most frequent response called for a subgroup analysis of apparently isolated VM on ultrasound. In this paper, we detail the diagnostic and clinical impact brought about by including MRI in the prenatal diagnostic pathway in 306 fetuses of the MERIDIAN cohort with VM as the only intracranial abnormality shown on antenatal ultrasound.
METHODS
The fetuses reported on in this paper were part of the MERIDIAN cohort; the overarching methodology of that study is reported elsewhere 2, 3 , but the parts relevant to this paper are summarized here. The MERIDIAN study was undertaken in accordance with The Medicines for Human Use (Clinical Trials) Regulations 2004 and ethical approval was obtained for a multicenter study through the Integrated Research Application System (62734). Inclusion criteria were pregnant women aged 16 years or over with a fetus with brain abnormality detected on ultrasound at a gestational age of 18 weeks or more, who had no contraindication to fetal MRI and gave written, fully informed consent to participate in the study. Recruitment was conducted from 16 fetal medicine units in the UK.
Ultrasound and MRI assessment
All ultrasound scans were performed by appropriately trained NHS fetal medicine consultants who recorded brain abnormalities using nomenclature of the ViewPoint antenatal ultrasound reporting software (GE Healthcare, Chalfont St Giles, UK). Following the ultrasound assessment, each woman had an MRI examination performed on a 1.5-T superconducting clinical MRI system, at one of six centers. The base requirement for the MRI assessment was to obtain T2-weighted images of the fetal brain in the three orthogonal planes and a T1-weighted ultrafast sequence in at least one plane (usually axial). The radiologist, who was aware of the diagnosis and had access to the full clinical ultrasound report, was required to comment on each brain abnormality recognized on ultrasound (using 'diagnosis excluded' if the finding was not present on MRI) and add extra anatomical diagnoses, where appropriate, using a similar form to the one used for the ultrasound examination.
In cases in which the pregnancy continued and the child survived, outcome reference data (ORD) were obtained from the clinical notes based on diagnoses made on postnatal neuroimaging studies up to the age of 6 months, with the exception of those fetuses in which VM was the only finding on both ultrasound and MRI but the size of the ventricles returned to normal as shown on ultrasound later in pregnancy or on neonatal imaging. In cases of termination of pregnancy (TOP), stillbirth or neonatal death, the ORD were based on autopsy and/or postmortem MRI. An independent pediatric neuroradiologist determined whether a full review by a multidisciplinary independent expert panel was required. Full review was required in every case unless (1) there was complete and unequivocal agreement between the abnormal findings on ultrasound, fetal MRI and ORD, or (2) VM was the only finding described on both ultrasound and MRI but the size of the ventricles had returned to normal as shown on ultrasound later in pregnancy or on neonatal imaging; the latter was counted as agreement in recognition that VM commonly resolves spontaneously during pregnancy.
The multidisciplinary independent expert panel consisted of three NHS consultants (a neuroradiologist, fetal medicine consultant and pediatric neurologist) from a center that did not recruit into MERIDIAN. They were asked to judge if the ultrasound-based and MRI-based diagnoses were in complete agreement with the ORD. The primary analysis in the MERIDIAN study centered on participants who underwent MRI within 14 days of ultrasound examination and for whom ORD were available and consisted of a calculation of diagnostic accuracy for ultrasound and MRI defined as: (true positives + true negatives)/total number of cases. Potential differences in the diagnostic accuracy of ultrasound and MRI were assessed by McNemar's paired binomial test. The subgroup reported in this paper consists of women recruited into the MERIDIAN study who were carrying a fetus with VM as the only intracranial finding on ultrasound. Fetal VM was categorized into three types based on the size of the largest trigone on ultrasound, in accordance with the classification used clinically in the referring centers, namely mild (10-12 mm), moderate (13-15 mm) or severe (≥ 16 mm).
Presence of other brain abnormalities
The main analysis consisted of calculations of diagnostic accuracy of ultrasound and MRI by comparing the ORD with the imaging-based diagnoses, including an assessment of the presence or absence of other brain abnormalities. Diagnostic accuracy was calculated for the entire subgroup and then in relation to the severity of VM diagnosed on ultrasound.
Assessment of ventricular size
The fetal medicine consultant performing the ultrasound examination was asked to record the ventricular measurements as left or right trigone and to specify which one was the near-field measurement. There are frequently problems in visualizing the near-field ventricle on ultrasound, and hence measurements may be difficult for that hemisphere. The trigone measurements made on MRI were recorded and compared with the ultrasound-derived measurements. First, we compared the type of VM (mild, moderate or severe) based on ultrasound and MRI measurements. Then, the absolute measurements of the left and right trigones on ultrasound and MRI were compared, and the difference described in order to judge the degree of agreement. The degree of agreement was also evaluated in relation to which measurement was near-field and which was far-field on ultrasound.
The risk of other brain abnormalities in relation to unilateral or asymmetric VM, as judged by MRI, was also assessed. In accordance with our previous publications, unilateral VM was defined as one trigone measuring ≥ 10 mm and the other being within the normal range, and asymmetric VM was defined as both trigones measuring ≥ 10 mm but having a difference of ≥ 3 mm between the two sides. Fisher's exact test was used to test for a statistically significant difference in other brain abnormalities between unilateral and asymmetric VM.
Effect on clinical management
The MERIDIAN study captured data from the fetal medicine specialists about changes in prognosis and clinical management brought about by fetal MRI, as described in detail elsewhere 3 , and we have included those data in the assessment of value of MRI data. The fetal medicine specialist was asked to record the predicted prognosis for each case before MRI was performed, i.e. based on ultrasound information only. Five categories were used: normal (no worse than the risk to a fetus without a demonstrable brain abnormality), favorable (normal neurological outcome expected in > 90% of cases), intermediate (normal neurological outcome expected in 50-90% of cases), poor (normal neurological outcome expected in < 50% of cases) and unknown.
At the subsequent consultation with the patient, at which time the MRI report was available, the clinician was asked to report whether MRI had provided any extra diagnostic information and to record the updated prognosis using the same five categories. For the purposes of this report, we described whether the prognosis remained the same, worsened or improved after MRI. This approach was straightforward when the prognosis was normal, favorable, intermediate or poor, and if the prognosis was unknown on both ultrasound and MRI. However, the decision was complicated when the prognosis on one imaging method was unknown but was specified on the other. In such cases, we made the following assignations:
• ultrasound prognosis 'Unknown', MRI prognosis 'Normal' or 'Favorable' = improved prognosis • ultrasound prognosis 'Unknown', MRI prognosis 'Intermediate' = no change in prognosis • ultrasound prognosis 'Unknown', MRI prognosis 'Poor' = worse prognosis • ultrasound prognosis 'Normal' or 'Favorable', MRI prognosis 'Unknown' = worse prognosis • ultrasound prognosis 'Intermediate', MRI prognosis 'Unknown' = no change in prognosis • ultrasound prognosis 'Poor', MRI prognosis 'Unknown' = no change in prognosis
If TOP was offered, clinicians were asked to report whether abnormalities seen on ultrasound only were sufficient to consider that option under Ground E of the Abortion Act 1967 (section 1(1)(d), 'substantial risk of serious mental or physical handicap') 4 and if this decision was still valid after the MRI information was available. Finally, the fetal medicine specialists were asked to rate the overall contribution of MRI to the final clinical management choice as having none, minor, significant, major or decisive effect.
RESULTS
The primary MERIDIAN cohort consisted of 570 fetuses with ORD and with MRI assessment done within 2 weeks of the referring ultrasound study. Of those, VM was part of the ultrasound diagnosis in 421 (73.9%) fetuses and VM was the only intracranial abnormality shown on ultrasound in 306 (53.7%) cases, which formed the basis of this report. The gestational age at which MRI was performed in this group is shown in Figure 1 ; 199/306 (65%) fetuses had their MRI examination between 18 and 23 weeks of gestation and 107/306 (35%) at, or after, 24 weeks. With respect to the severity of VM, 244/306 (80%) fetuses had mild VM, 36/306 (12%) moderate VM and 26/306 (8%) severe VM, according to the measurement of the largest trigone on ultrasound. Fourteen (5%) fetuses had known non-brain abnormalities, including five cardiac abnormalities, three thoracic, three head and neck, two abdominal and one genitourinary, and 11 (4%) fetuses had chromosomal or genetic abnormalities (trisomy 21 (n = 7), Aicardi syndrome (n = 1), congenital myotonic dystrophy/pneumothorax (n = 1), karyotype 47 XYY (n = 1), trisomy 7q (n = 1)).
Presence of other brain abnormalities
Brain abnormalities additional to VM were found on ORD in 31/306 (10.1%) fetuses, of which 17/199 (8.5%) were in the 18-23-week group and 14/107 (13.1%) in the ≥ 24-week group. Those brain abnormalities involved 5.7% (14/244) of fetuses with mild VM, 19.4% (7/36) of fetuses with moderate VM, and 38.5% (10/26) of fetuses with severe VM (Table 1 ). The additional brain abnormalities consisted of failed commissuration (agenesis and hypogenesis of the corpus callosum) in 17/31 (55%) cases (with three cases also having other significant brain/eye abnormality), encephalomalacia and/or intracranial hemorrhage in 8/31 (26%), cortical formation abnormality in 4/31 (13%) and absent cavum septi pellucidi due to septo-optic dysplasia in 2/31 (6%). Acquired brain pathologies (i.e. encephalomalacia and/or intracranial hemorrhage) accounted for 1/17 (6%) cases of other brain abnormalities in the 18-23-week group and 7/14 (50%) cases in the ≥ 24-week group, and were most frequently found in conjunction with (Table 2 ). In all but one case, the degree of disagreement was only by one category, including four cases in which the MRI measurements of the trigones were within normal range.
In 42/275 (15%) cases, only one trigone could be measured on ultrasound because of near-field effects, so it was only possible to compare the absolute measurements of 508 trigones on ultrasound and MRI (both trigones in 233 cases and one trigone in 42 cases; Figure 7 ). In 142/508 (28%) cases, the trigone measurements made on ultrasound and MRI agreed to the nearest millimeter, 326/508 (64%) measurements were within ± 1 mm and 409/508 (81%) were within ± 2 mm. The distribution of the differences was symmetrical, indicating that there is no tendency for MRI to either underestimate or overestimate systematically the trigone size compared with ultrasound ( Figure 7) .
It was possible to make a direct comparison of trigone measurements made on ultrasound and MRI in 197 fetuses (394 trigones) for which information on near-field and far-field ultrasound measurements was available. In 36 cases, the near-field/far-field information was not recorded and in 42 cases it was only possible to measure the far-field trigone on ultrasound. In the 197 cases that could be assessed, there was no significant difference in the level of agreement between the measurements made on near-field (difference (modulus) 1.6 ± 1.8 mm) and on far-field (difference 1.5 ± 1.9 mm), indicating close correlation in those ventricles that could be visualized on ultrasound.
On MRI, 109/306 (35.6%) fetuses had unilateral VM, 44/306 (14.4%) had asymmetric VM and 149/306 (48.7%) had symmetric VM. In four fetuses, VM was excluded on MRI. Other brain abnormalities were found in 2/109 (1.8%) fetuses with unilateral VM (both with cortical formation abnormalities) and 5/44 (11.4%) fetuses with asymmetric VM (four cases of failed commissuration (with a cortical formation abnormality in one) and one case of intracranial hemorrhage) with a statistically significant difference of 9.6% (P = 0.0213). This is compared with a rate of brain abnormalities of 23/149 (15.4%) in fetuses with symmetric VM.
Effect on clinical management
It was possible to study effects on prognosis/management brought about by MRI assessment in 295 fetuses (Table 3) . As a consequence, the decision to offer TOP was changed after MRI in 22/295 (7.5%) fetuses. Termination was performed in 14/295 (4.7%) cases. The effect of MRI on clinical management in the whole group of 295 fetuses according to the fetal-maternal expert was described as none in 14% of cases, minor in 61%, significant in 21%, major in 4% and decisive in 0.3%. A detailed summary of the effect of MRI assessment on prognosis and management in the 29/295 fetuses that had additional brain pathology other than VM confirmed by ORD, and complete prognosis/management data are presented in Table 3 . Prognosis was considered worse after MRI in 14/29 (48.3%) cases and the effect of MRI on overall clinical management was 'significant', 'major' or 'decisive' in 15/29 (51.7%) cases.
DISCUSSION
VM refers to enlargement of the ventricular system and can involve some or all of the cerebral ventricles but the clinical assessment of ventricular size on antenatal ultrasound is centered on the trigones of the lateral ventricles. To reduce the subjective nature of assessing 'enlarged ventricles', ultrasonographers have devised a reproducible method for assessing the trigone size of the lateral ventricles 5 . A measurement of ≥ 10 mm is considered to be abnormal at any stage of pregnancy as this is approximately 4 SD above the mean. This definition is generally accepted for fetal VM in the UK and was used in the MERIDIAN study. It should be appreciated that it is possible to have VM involving other parts of the ventricular system (e.g. frontal horns) with trigone measurements < 10 mm; these cases are relatively rare and have not been included here. VM can be categorized further based on the largest trigone size. The MERIDIAN recruiting centers use three categories: mild (10-12 mm), moderate (13-15 mm) and severe (≥ 16 mm). The extra level of detail allows correlation with long-term neurodevelopmental outcomes in cases in which VM is the only abnormality. All referring centers in the MERIDIAN study regard isolated mild VM as low risk and place such fetuses in the favorable ('normal neurological outcome expected in ≥ 90% of cases') group. Specifically, half quote ≥ 90% chance of normal outcomes and the other half quote ≥ 95%. There was considerable variation in the prognosis given to fetuses with moderate VM. Of the 36 cases of moderate VM on ultrasound, full prognosis and management data were available in 34 cases. The referring fetal medicine consultants gave a favorable prognosis to seven of the 34 fetuses, intermediate prognosis to 21, poor prognosis to five and 'not known' to one, before fetal MRI examination. This is in spite of robust information in published literature that mostly describes 'intermediate' prognosis. Similarly, there is robust published literature on the 'poor' prognosis for fetuses with severe VM 6 , but out of the 24 fetuses in this study with severe VM and full prognosis/management data, eight were given an intermediate prognosis and 16 a poor prognosis after ultrasound assessment alone. This indicates a degree of clinical uncertainty in the UK. Future follow-up studies of the MERIDIAN cohort may provide data to clarify this uncertainty.
The overall rates of unilateral and asymmetric VM were in line with those of our previous publications 7, 8 . In this study we showed that the risk of another brain abnormality is reduced in fetuses with unilateral VM when compared with those with bilateral VM (P = 0.0213). This is in comparison with cases of asymmetric VM in which the risk of having another brain abnormality was no different from the risk in the bilateral VM group.
There is now considerable evidence supporting the value of fetal MRI in diagnosing fetal brain abnormalities, based on systematic reviews [9] [10] [11] [12] and our prospective study 3 . Whilst designing the MERIDIAN study, fetal medicine focus groups were formed with the purpose of identifying important issues that should be addressed by the study in order to improve clinical practice. One major recommendation was the need to perform separate analyses on anatomical subgroups of fetal brain abnormalities, including isolated VM. Some questions related to differences in the technical aspects of measuring the ventricles on ultrasound and MRI; specifically, there was an impression that MRI overestimated ventricle size as compared with ultrasound. The depth of problems arising from near-field effects on ultrasound was also identified for investigation. We attempted to address those issues here, but the leading issue raised by the focus groups was the widely held belief that when mild VM is the only intracranial finding on ultrasound, the diagnosis is invariably correct and does not require MRI. This is of importance to healthcare funders because, if that opinion is correct, the resources required to provide clinical service are significantly reduced.
The subgroup analysis of the MERIDIAN cohort presented here, including cases with VM as the only abnormal intracranial finding on ultrasound, shows that, according to ORD, additional brain abnormalities were present in 31/306 (10.1%) fetuses overall and there was a higher rate of brain abnormalities in the more severe VM categories, which is comparable with our previous report, although ORD were not available in that study 7, 8 . Additional brain abnormalities were shown in 5.7% (14/244) of fetuses with mild VM, 19.4% (7/36) of fetuses with moderate VM, rising to 38.5% (10/26) of fetuses with severe VM, compared with 6%, 14% and 57%, respectively, in our previous work. Fetal MRI identified 27/31 of the other brain abnormalities and improved diagnostic accuracy in all VM categories.
A factor that has the potential to reduce the diagnostic accuracy of ultrasound is the deleterious results of the near-field effect. Although there is good correlation of trigone sizes between ultrasound and MRI when trigones can be visualized on ultrasound, we have shown that, in 15% of the reported cases, one cerebral hemisphere was not visualized to a degree that the trigone of the lateral ventricle could not be measured. This is likely to be an important diagnostic limitation generally, and particularly in cases of unilateral pathology if it involves the 'near-field' hemisphere. This can interfere with the detection of both developmental brain pathology (cortical formation abnormalities are frequently unilateral) and acquired pathology (e.g. hemorrhage and encephalomalacia).
MRI had a major clinical impact in cases of ultrasound-diagnosed VM. After MRI, the prognosis was changed in 23.4% of cases and the overall effect on clinical management was considered to be 'significant', 'major' or 'decisive' in over 25% of cases. The decision to offer TOP was changed in 7.5% of cases after MRI, including reversal of the ultrasound-based decision to offer TOP in eight fetuses and offering TOP to a further 14 fetuses based on additional brain anomalies other than VM.
In conclusion, based on our current data, we believe that fetal MRI should be offered to all women in whom a diagnosis of VM as the sole intracranial abnormality is made on ultrasound. As a minimum, women should be advised that, even in cases of mild VM, there is a 1:20 chance that additional brain abnormalities have been overlooked on ultrasound and this increases with higher severity of VM. The absolute size measurements of the trigones of the lateral ventricles are very similar on ultrasound and MRI, and thus MRI does not appear to systematically overestimate ventricle size.
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